dc.contributor.author | Eivazi-Ziaei, J | |
dc.date.accessioned | 2018-08-26T06:34:10Z | |
dc.date.available | 2018-08-26T06:34:10Z | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/43924 | |
dc.description.abstract | To investigate protocols of remission induction therapy for prevention of morbidity of acute myeloid leukemia.The responses of 150 patients to "2+5" and "3+7" protocols during 1996-2003 were assessed and analyzed with the Chi-Square method.Complete remission was observed in 30% of cases treated with 2 days of daunorubicin and 5 days of cytarabine (2+5 regimen). Remission was increased to 52.5% when patients were treated with 3+7 regimens with the same drugs. Partial remission resulted in 25 and 10 percent of cases, respectively.As in previous studies the 3+7 regimen was demonstrated to be more effective than the 2+5 regimen in our hospital (p=0.0009). | |
dc.language.iso | English | |
dc.relation.ispartof | Asian Pacific journal of cancer prevention : APJCP | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Antibiotics, Antineoplastic | |
dc.subject | Antimetabolites, Antineoplastic | |
dc.subject | Cytarabine | |
dc.subject | Daunorubicin | |
dc.subject | Drug Administration Schedule | |
dc.subject | Humans | |
dc.subject | Iran | |
dc.subject | Leukemia, Myeloid, Acute | |
dc.subject | Middle Aged | |
dc.subject | Remission Induction | |
dc.subject | Retrospective Studies | |
dc.title | Control of acute myeloid leukemia morbidity in northwest Iran. | |
dc.type | article | |
dc.citation.volume | 6 | |
dc.citation.issue | 4 | |
dc.citation.spage | 472 | |
dc.citation.epage | 3 | |
dc.citation.index | Pubmed | |